Alzheimer disease treatment

Alzheimer disease Treatment of mild to moderate dementia of the Alzheimer type. 

Schwarz RD, Callahan MJ, Davis RE, et al Selective muscarinic agonists for Alzheimer disease treatment, in Alzheimer Disease Therapeutic Strategies. Edited by Giacobini E, Becker R. Boston, MA, Birkhauser, 1994, pp 224-228 Schwarz S, Pohl P Steroids and opioid receptors. J Steroid Biochem Mol Biol 48 391-404, 1994... 

In summary, the steadily increasing size of geriatric populations in developed countries and the resultant increases in age-related diseases of the brain have provided the impetus for intensive study of the processes underlying neurodegeneration. A better understanding of these processes will likely lead to better methods of treatment not only for progressive memory disorders such as Alzheimer disease, but also for motor disorders such as amyotrophic lateral sclerosis, and cerebrovascular disorders such as stroke. 

Zhang, Z., Wang, X., Chen, Q. etal. (2002). Clinical efficacy and safety ofhuperzine Ain treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. National Medical Journal of China, 82( 14), 941-5. 

Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT Jr. Apolipoprotein E is a kinetic but not a thermodynamic of amyloid formation implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 1995 92 763-767. 

Diesner JW (1998). A review of estrogen replacement therapy use in the prevention and treatment of Alzheimer disease. Primary Care Update for OB/GYNS, 5, 50-53. 

Rottkamp CA, Nunomura A, Hirai K, Sayre LM, Perry G and Smith MA (2000). Will antioxidants fulfill their expectations for the treatment of Alzheimer disease Mechanisms of Ageing and Development, 116, 169-179. 

Poirier J, Delisle MC, Quirion R et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995 92[26] 12260-12264. 

Small, G. W., Rabins, P. V., Barry, P. P. et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer s Association, and the American Geriatrics Society. JAMA 278(16) 1363-1371,1997. 

Poirier, J., et al., "Apolipoprotein E4 Allele as a Predictor of Cholinergic Deficits and Treatment Outcome in Alzheimer Disease," Proc. Natl. Acad. Sci. U.S.A., 92,... 

Pharmacogenomics may be beneficial to people of color because of their high rates of morbidity and mortality from certain cancers, hypertension, cardiovascular disease, asthma, HIV /AIDS, Alzheimer disease, clinical depression, and other diseases. Thus more effective therapies help those individuals most in need of treatment. 

Pharmacogenomic Response to a Multifactorial Treatment in Alzheimer Disease... 

Cacabelos, R., Alvarez, X.A., Lombardi, V., et al. (2000) Pharmacological treatment of Alzheimer disease From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today, 36, 415 99. 

Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimers Dis Assoc Disord 2003 17 S105-S113. 

Bai DL, Tang XC, He XC. (2000) Huperzine A, a potential therapeutic agent for treatment of Alzheimers disease. CurrMed Chem 7 355-374. 

Hake AM, Use of cholinesterase inhibitors for treatment of Alzheimer disease, Cleve Clin68 608-609, 613-614, 616, 2001. 

Greig NH, Utsuki T, Yu QS, A new therapeutic target in Alzheimer s disease treatment, attention to butyrylcholinesterase, Curr Med Res Opin 17 159—165, 2001. 

Grieg NH, Pei XH, Soncrant T, Ingram DK, Brossi A, Phenserine and ring C hetero-analogues, Drug candidates for treatment of Alzheimers disease, Med Res Reviews 15 3—31, 1995. 

Nonannulated aminopyrans 22 and tetrahydrochromenes 104 were used in the synthesis of heteroanalogs 294 and 295 of tacrine 302, a cholinesterase inhibitor applied in Alzheimer s disease treatment (01BML727, 02BML2077, 04BMC2199, 05BMC1167, 06BMC8176). 

A range of legal drugs is sold by the pharmaceutical industry to treat illnesses of the nervous system. Advances in our understanding of the structure and function of the nervous system has accelerated the development of chemicals for treating diseases such as Parkinson s syndrome, Alzheimer s disease, and mild depression. The treatment of mild depression with drugs like Prozac is a billion dollar industry. On the other hand, some drugs may produce undesirable nervous system side effects that can limit their utility in disease treatment. The anticancer... 

Tariot PN, Farlow MR, Grossherg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease aheady receiving donepezU a randomized controlled trial. JAMA 2004 291(3) 317-24. 

Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000 283 1007-15. 

FK-960 was initially developed for treatment of Alzheimer disease, but it has been abandoned for this indication. However, it is still under clinical trials for therapy of cognition disorders related to schizophrenia. 

Triflusal, a known antiplatelet agent used in the treatment of thromboembolic disorders, is currently being evaluated for use in Alzheimer disease. It has been shown to inhibit the activation of the mediators of neuroinflammation. 

HCT-1026 (nitwflurbipwfen) is a nitric oxide-donating derivative of the NSAID flurbiprofen. It is undergoing Phase 1 clinical evaluation for the treatment of Alzheimer disease, but it is more advanced (Phase 11) for overactive bladder and osteoporosis. 

---